Financiere de Tubize SA
XBRU:TUB

Watchlist Manager
Financiere de Tubize SA Logo
Financiere de Tubize SA
XBRU:TUB
Watchlist
Price: 141 EUR -0.56% Market Closed
Market Cap: 6.3B EUR
Have any thoughts about
Financiere de Tubize SA?
Write Note

Net Margin
Financiere de Tubize SA

0%
Current
3 065%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
183.9m
/
Revenue
0

Net Margin Across Competitors

Country BE
Market Cap 6.3B EUR
Net Margin N/A
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 757B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 350.9B USD
Net Margin
17%
Country US
Market Cap 252.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 150.9B USD
Net Margin
7%
No Stocks Found

Financiere de Tubize SA
Glance View

Market Cap
6.3B EUR
Industry
Pharmaceuticals

Nestled in the heart of Belgium, Financiere de Tubize SA stands as a distinctive player in the world of investment holding companies, anchored in its robust shareholding strategy. Unlike many investment entities that diversify their portfolios across industries, Tubize has channeled its focus largely into the pharmaceutical sector through its significant shareholding in UCB, a global biopharmaceutical giant. This singular focus reflects a strategic commitment to capitalize on the growth and innovations within the healthcare industry, leveraging UCB's extensive research capabilities and expansive market presence. By holding a concentrated position in a company with established credentials in developing treatments for severe diseases, Tubize essentially acts as a conduit for investors to gain exposure to the burgeoning potential of biopharmaceutical advancements. The financial success of Financiere de Tubize SA is intricately tied to the performance of UCB. As UCB thrives and expands through its innovative drug developments and strategic market expansions, Tubize enjoys a consistent flow of dividends and capital appreciation. This dividend income underpins Tubize's operational model, allowing it to reinvest in its core holdings and distribute earnings to its own shareholders, thereby creating a cyclical flow of wealth generation and sustainability. Tubize's approach is akin to a watchful guardian, closely monitoring UCB's strategic paths while maintaining an investment structure that keeps administrative and operational costs minimal. Through such a streamlined focus, Financiere de Tubize SA offers investors a targeted and long-term pathway into the pharmaceutical sector, marked by careful oversight and strategic clarity.

TUB Intrinsic Value
27.4 EUR
Overvaluation 81%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
183.9m
/
Revenue
0
What is the Net Margin of Financiere de Tubize SA?

Based on Financiere de Tubize SA's most recent financial statements, the company has Net Margin of 0%.